Cyclerion Therapeutics
CYCN
CYCN was delisted on the 8th of September, 2026.
17 hedge funds and large institutions have $249K invested in Cyclerion Therapeutics in 2026 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 6 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
3.42% less ownership
Funds ownership: 7.55% → 4.13% (-3.4%)
11% less funds holding
Funds holding: 19 → 17 (-2)
17% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 6
34% less capital invested
Capital invested by funds: $376K → $249K (-$127K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$58.7K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$26K |
| 3 |
KA
Kovack Advisors
Ft. Lauderdale,
Florida
|
+$14.2K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$4.29K |
| 5 |
CIAM
Caitong International Asset Management
Hong Kong
|
+$6 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SL
Siren LLC
Greenwich,
Connecticut
|
-$147K |
| 2 |
Two Sigma Investments
New York
|
-$52.8K |
| 3 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$12.7K |
| 4 |
Citigroup
New York
|
-$11.5K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$4.01K |
CYCN Hedge Fund Activity: Q1 2026 in Review
17 of the 8,196 institutional investors tracked by Wall St. Rank reported a position in Cyclerion Therapeutics (CYCN) for Q1 2026, worth a combined $249K — down 34% from $376K a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of CYCN and 5 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 2 added.
The largest buyer was Geode Capital Management, adding an estimated $58.7K. The largest seller was Siren LLC, exiting entirely with an estimated $147K sold.
- 17 institutional investors held Cyclerion Therapeutics (CYCN) as of Q1 2026, down from 19 in Q4 2025.
- Funds reported $249K of Cyclerion Therapeutics stock for Q1 2026, down 34% quarter-over-quarter.
- 5 funds opened new Cyclerion Therapeutics positions in Q1 2026 and 6 closed out, a net change of -1 holder.
- The largest Cyclerion Therapeutics buyer in Q1 2026 was Geode Capital Management, an estimated $58.7K added.
- The largest Cyclerion Therapeutics seller in Q1 2026 was Siren LLC, an estimated $147K sold.
Based on aggregated 13F filings for Q1 2026.